lifestyle.rogueimc.org

Author: Decoy Therapeutics, Inc

Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston

April 27, 2026
Decoy Therapeutics Builds Momentum with Accelerating Execution, Entering a Highly Catalytic Phase with a Clearly Defined Path to Clinical Development of its Antiviral Pipeline

April 9, 2026
Decoy Therapeutics to Participate in Virtual Investor Closing Bell Event Highlighting Business Outlook for 2026

April 6, 2026
Decoy Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

April 2, 2026
Decoy Therapeutics Enters Strategic Partnership with Quantori to Deploy Google Cloud-native Integrated AI-Driven Peptide Design and Molecular Simulation Platform

March 11, 2026
Decoy Therapeutics Announces 1-for-12 Reverse Stock Split

March 5, 2026
Decoy Therapeutics Joins Webull Corporate Connect Service Platform

February 12, 2026
Decoy Therapeutics to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

February 11, 2026
Decoy Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recently Announced Global Access Commitment Agreement

February 10, 2026
Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform

January 13, 2026